TITLE

The Industry

PUB. DATE
June 2005
SOURCE
Pharmaceutical Representative;Jun2005, Vol. 35 Issue 6, p10
SOURCE TYPE
Periodical
DOC. TYPE
Article
ABSTRACT
The article presents information related to pharmaceutical industry in the U.S. Pfizer Inc., New York, has entered into an exclusive global agreement to develop and commercialize Wellesley, Massachusetts -based Coley Pharmaceutical Group Inc.'s phase II toll-like receptor 9 agonist ProMune (CPG 7909) for the potential treatment, control and prevention of cancers. Jazz Pharmaceuticals Inc.. Palo Alto, California and Minnetonka, Minnesota -based Orphan Medical Inc. have announced a merger agreement under which Jazz will acquire Orphan for $10.75 per share.
ACCESSION #
17482048

 

Related Articles

  • Pfizer Boosts Vaccine Pipeline With $164M Deal.  // Bioworld Week;11/26/2007, Vol. 15 Issue 48, p2 

    The article reports on the acquisition of Coley Pharmaceutical Group Inc. by Pfizer Inc. of New York to boost vaccine and biological development pipeline in a deal worth about $164 million. Coley specializes in developing vaccines and drugs that stimulate or inhibit Toll-like receptors (TLRs) to...

  • Pfizer Boosts Vaccine Pipeline With $164M Deal For Coley. Young, Donna // BioWorld Today;11/19/2007, Vol. 18 Issue 225, p1 

    The article reports on the plan by Pfizer Inc. to acquire Coley Pharmaceutical Group Inc. Pfizer plans to acquire Coley as part of its effort to boost its vaccine and biological development pipeline. Coley's shares rose with the news of the acquisition. Under terms of the deal, Pfizer will pay...

  • Pfizer to acquire Coley Pharmaceutical Group.  // PharmaWatch: Biotechnology;Jan2008, Vol. 7 Issue 1, p18 

    The article reports on a $164 million plan of Pfizer Inc. to acquire Coley Pharmaceutical Group Inc., a biopharmaceutical company which specializes in vaccine adjuvant technology and immunomodulatory drugs. Pfizer is to pay for the common stock of Coley for $8 per share which will have an...

  • Jazz Adopts Orphan Medical.  // Chemical Market Reporter;4/25/2005, Vol. 267 Issue 17, p8 

    The article reports that Palo Alto, California-based Jazz Pharmaceuticals Inc. will acquire Orphan Medical Inc. in a merger agreement valued at roughly $122.6 million, or $10.75 per share of Orphan Medical stock. Following the merger, Orphan Medical will become a wholly owned subsidiary of Jazz...

  • Strengths.  // PharmaWatch: CNS;Feb2012, Vol. 11 Issue 2, p30 

    The article discusses the strengths aspects of the strenghts, weaknesses, opportunities, and threats (SWOT) analysis of pharmaceutical company Pfizer Inc. It talks about the dominance of the company in the industry's merger and acquisition (M&A) activity and the company's strong commercial...

  • Weaknesses.  // PharmaWatch: CNS;Feb2012, Vol. 11 Issue 2, p31 

    The article discusses the weaknesses and opportunities aspects of the strengths, weaknesses, opportunities, and threats (SWOT) analysis of pharmaceutical company Pfizer Inc. It talks about the difficulty for the company to continue growing sales with using a large-scale of merger and acquisition...

  • Threats.  // PharmaWatch: CNS;Feb2012, Vol. 11 Issue 2, p32 

    The article discusses the threats aspects of the strengths, weaknesses, opportunities, and threats (SWOT) analysis of pharmaceutical company Pfizer Inc. It notes that the company's further large-scale merger and acquisition (M&A) activity will lead to difficulty in achieving organic sales...

  • Pharmaceutical mergers drive big growth at credit union. Merx, Katie // Crain's Detroit Business;7/12/2004, Vol. 20 Issue 28, p5 

    Pharmaceutical company consolidation has been good for Auburn Hills' Parda Federal Credit Union. Founded by seven Detroit-based Parke-Davis employees in 1937, Parda has grown as Parke-Davis merged with pharmaceutical giant Warner-Lambert Co. in the 1970s and into Pfizer Inc. in 2000. Pfizer's...

  • The Industry.  // Pharmaceutical Representative;Jan2008, Vol. 38 Issue 1, p8 

    The article offers news briefs related to the pharmaceutical industry in the U.S. Celgene Corp. in Summit, New Jersey, is planning to acquire the oncology and hematology-focused company Pharmion Corp. for $2.9 billion. Nycomed Inc. in Melville, New York has agreed to acquire Bradley...

Share

Read the Article

Courtesy of VIRGINIA BEACH PUBLIC LIBRARY AND SYSTEM

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics